H.B. has served as a consultant/advisory board member for Janssen, Astellas, Astra Zeneca, Merck, Pfizer, Foundation Medicine, Amgen, Bayer, Oncorus, LOXO, Daicchi Sankyo and Curie Therapeutics (for work unrelated to the present study). H.B.’s institution has received research funding from Janssen, AbbVie/Stemcentrx, Eli Lilly, Astellas, Millennium, Bristol Myers Squibb, Circle Pharma, Daicchi Sankyo and Novartis (for work unrelated to the present study). M.K.B. declares no competing interests.